Tags : Primary Endpoints

Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary

Tuba Khan March 11, 2021

Shots: The P-III REMDACTA study involves assessing Actemra/RoActemra (tocilizumab) + Veklury (remdesivir) vs PBO + Veklury in hospitalized patients with severe COVID-19 pneumonia receiving SOC The study did not meet […]readmore

Biotech

Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for

Vartika Singh September 6, 2018

Shots: The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for […]readmore

Tags : Primary Endpoints

Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary

Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Primary Endpoints

Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary

Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company